Accretion Pharmaceuticals IPO Allotment Status: Check Latest GMP, Steps to Verify Status

Accretion Pharmaceuticals Limited has finalised the allotment of its initial public offering (IPO) on Monday, May 19, 2025. The ₹29.75 crore issue, comprising a fresh issuance of 2.94 million equity shares, was open for subscription from May 14 to May 16. The IPO witnessed robust investor interest, being oversubscribed by 7.32 times. 

Subscription Details

The IPO was priced in the range of ₹96 to ₹101 per share, with a minimum lot size of 1,200 shares. The retail investor segment saw significant participation, subscribing 8.18 times, while the Non-Institutional Investor (NII) category was subscribed 2.65 times. The Qualified Institutional Buyers (QIB) segment led the demand, with a subscription of 10.97 times.

How to Check Allotment Status

Investors who applied for shares in the IPO can check their allotment status through the following methods:

Via KFin Technologies (Registrar’s Website):

1. Visit the KFinTech IPO allotment page: https://ris.kfintech.com/ipostatus/
   
   
2. Select ‘Accretion Pharmaceuticals Limited’ from the dropdown.
   
   
3. Choose one of the following identification methods:
   

• PAN
  
  
• Application Number
  
  
• DP Client ID
  

1. Enter the details and captcha code.
   
   
2. Click on ‘Submit’ to view your allotment status.
   
   

Via NSE Website:

1. Go to https://www.nseindia.com/invest/check-ipo-allotment-status
   
   
2. Select the IPO name – ‘Accretion Pharmaceuticals’.
   
   
3. Enter your application number or PAN details.
   
   
4. Complete the captcha verification.
   
   
5. Click ‘Search’ to see your status.
   

Refunds for unsuccessful applicants will be processed on May 20, 2025, and successful applicants will receive their shares in demat accounts by the same day.

Grey Market Premium and Listing Expectations

The grey market premium (GMP) for Accretion Pharmaceuticals' shares has remained flat at ₹0, indicating neutral market sentiment ahead of the listing. This suggests that the shares may list at par with the issue price, reflecting cautious optimism among investors.

Note: The Grey Market Premium (GMP) is not an official price and is based on Market Speculation.

Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market.

Source: Business Standard Dated May 19, 2025

Company Overview

Established in 2012, Accretion Pharmaceuticals Limited is engaged in the manufacturing and marketing of a diverse range of pharmaceutical products, including tablets, capsules, oral liquids, and various external preparations. The company also offers contract manufacturing services to other pharmaceutical entities. Its manufacturing facility is located in Sanand, Ahmedabad, Gujarat. The company holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, underscoring its commitment to quality and environmental management standards.

Utilisation of IPO Proceeds

The net proceeds from the IPO are earmarked for capital expenditure, including the acquisition of new equipment and upgradation of existing manufacturing facilities. Additionally, funds will be allocated towards the repayment or prepayment of certain borrowings, meeting working capital requirements, and general corporate purposes. 

Conclusion

Accretion Pharmaceuticals' successful IPO subscription reflects investor confidence in the company's business model and growth prospects. However, the flat GMP suggests a cautious approach by the market ahead of the listing. The company's performance post-listing will be closely watched by investors and market analysts alike.